Home Tags Salvage

Tag: Salvage

Trial Shows 92% Objective Response Rate in the Evaluation of Brentuximab...

Data presented at the 2014 Annual Bone Marrow Transplant (BMT) Tandem Meetings organized by The American Society for Blood and Marrow Transplantation and the Center for International Blood & Marrow Transplant Research being held in Grapevine (Dallas), Texas, February 26 - March 2, 2014, highlights the benefits of brentuximab vedotin (Adcetris®; Seattle Genetics) in various treatment schedules for hard to treat cancers.